Back to results
US 2022/0064636 A1Published application
Modified oligomeric compounds and uses thereof
AssigneeIonis Pharmaceuticals, Inc.
InventorsPunit P. Seth, Michael T. Migawa, Graeme C. Freestone
Life of this patent
Estimating the term…
Abstract
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside.
Claims26
-202. (canceled)
An oligomeric compound comprising a modified oligonucleotide consisting of 15-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside, wherein at least one stereo-non-standard nucleoside has the structure of Formula II or of Formula V:
- wherein one of J3 and J4 is H and the other of J3 and J4 is selected from H, OH, F, OCH3, OCH2CH2OCH3, O—C1-C6 alkoxy, and SCH3;
- and wherein
- Bx1 is a is a heterocyclic base moiety;
- wherein one of J9 and J10 is H and the other of J9 and J10 is selected from H, OH, F, OCH3, OCH2CH2OCH3, O—C1-C6 alkoxy, and SCH3;
- and wherein
- Bx2 is a is a heterocyclic base moiety.
3 more elements
Dependencies are inferred from the claim text.